* American Diabetes Association, statistics about diabetes.
# Refers to SmartGuard^™ Auto Mode. Some user interaction required. Individual results may vary.
§ Customer training phase – data on file.
ß BG testing, proper mobile device, settings required. See bit.ly/GCRisks. Optional SugarIQ^™app pictured.
‡ At the time of manufacture and when the reservoir and tubing are properly inserted, your pump is waterproof. It is protected against the effects of being underwater to a depth of up to 12 feet (3.6 meters) for up to 24 hours. This is classified as IPX8 rating. See user guide for more details. The sensor and transmitter are water-resistant at 8 feet (2.4 meters) for up to 30 minutes. CGM readings may not be transmitted from the CGM to the pump while in water.
† WARNING (For MiniMed™ 670G System Users Ages 7-13):
The low sensor glucose alert functionality is distinct from the automated insulin dosing function of the MiniMed™ 670G system. When used in Auto Mode, the MiniMed™ 670G system has been shown to be safe and effective for its intended use in this population. However, do not rely solely on the use of a low sensor glucose (SG) value for “Alert on Low” or “Alert before Low” for alerts set at 50 mg/dL and 60 mg/dL. A low sensor glucose alert may not reflect the user’s true blood glucose at these levels or may not alert. Do not ignore symptoms of low glucose. Always confirm your sensor glucose readings with your blood glucose meter and treat according to the recommendations of your healthcare professional. Solely relying on these sensor glucose alerts and readings for treatment decisions could result in missing severe hypoglycemia (low blood glucose) events.
1. Smart CGM predicts future high and low sensor glucose events up to 60 minutes in advance and provides access to additional algorithms and insights that can inform users of clinically relevant glucose patterns.
2. Hanas R, Adolfsson P, Elfvin-Akesson K et al. Indwelling catheters used from the onset of diabetes decrease injection pain and pre-injection anxiety. J Pediatr. 2002;140(3)315-320
3. Riley D, Raup G. Impact of a subcutaneous injection device on improving patient care. Nurs Manage. 2010;41(6):49-54